Pancreatic Cancer Clinical Trial
Official title:
Clinical Evaluation Of NCLE in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas
This study focuses on three different lesions: pancreatic cysts, lymph nodes near the
gastrointestinal tract and pancreatic masses.
On one hand, the results obtained during previous studies are more advanced for the
assessment of the diagnostic performance of Cellvizio needle-based Confocal Laser
Endomicroscopy (nCLE) system for Pancreatic cysts. Safety and technical feasibility have
already been performed, and an interpretation criteria classification exists. On the other
hand, results for pancreatic masses and Lymph nodes are less developed.
The study therefore comprises two sub-studies, one on the pancreatic cysts, and another on
pancreatic masses and lymph nodes.
1. Cysts The primary hypothesis of the study is that using nCLE in addition to EUS-FNA and
tissue sampling allows better characterization of pancreatic cysts and improves
appropriate therapeutic decision-making.
For physicians, integrating nCLE into the diagnostic algorithm of pancreatic cysts could
impact patient management by :
- Ruling out malignancy for patients with benign appearing nCLE images.
- Characterizing more malignant tumors in the pancreas.
2. Pancreatic masses and Lymph nodes The primary hypothesis of the study is that in vivo
imaging of lymph-nodes near the gastrointestinal tract and pancreatic masses during
EUS-FNA procedures is feasible and that descriptive criteria can be defined to further
differentiate the different types of lesions.
1. Medical background Pancreatic cancer is the fourth leading cause of cancer-related death
in the United States. This disease is associated with a high mortality rate: the 5-year
survival rate is estimated to be 4%. This is mainly due to the fact that the disease is
often discovered at an already advanced disease state, which carries a dismal prognosis.
1.1. Pancreatic Cysts
Pancreatic cysts are quite rare, but are being increasingly recognized due to the
expanding use of cross-sectional imaging. They are classified into three main classes:
- Pseudocysts
- Serous cysts : either serous cystic neoplasms (SCN) or Solid pseudo-papillary
neoplasm (SPN)
- Mucinous cystic neoplasms : either Intraductal Papillary Mucinous Neoplasm (IPMN)
or mucinous cystadenomas/mucinous cystadenocarcinoma(MCN) Mucinous cystic neoplasms
are considered to be malignant or pre-malignant and are considered for surgical
resection, whereas pseudocysts and serous cysts are considered benign and with a
low potential for malignancy. Pseudocysts and serous cysts are usually only
considered for surgical resection when symptomatic or enlarging.
1.2. Pancreatic masses Pancreatic solid masses can be either exocrine or endocrine
tumors, or metastatic.Exocrine tumors are by far the most common type of pancreas
cancer. Most of them are malignant. About 96% of cancers of the exocrine pancreas are
adenocarcinomas, which is the most aggressive form of pancreas cancer.Endocrine tumors
are uncommon. They represent 4% of pancreas tumors. They are known as neuroendocrine
tumors (NETs), or islet cell tumors. These tumors can be benign or malignant.
1.3. Lymph nodes Lymph nodes are examined in a patient with a suspicion of, or
confirmed, cancer, as part of the staging. They may be either normal, inflammatory, or
malignant.
2. Clinical background
2.1. EUSFNA Endoscopic Ultrasound (EUS) is the diagnostic method of choice when a
pancreatic lesion is found incidentally on cross-sectional imaging. Endoscopic
UltraSound-guided Fine Needle Aspiration (EUS FNA) (respectively Endobronchial
Ultrasound-guided Fine Needle Aspiration (EBUS FNA)) are procedures where a target
tissue in proximity to the GI tract (respectively the pulmonary tract) is biopsied using
a fine needle guided in real time by an ultrasound probe fixed at the tip of an
endoscope.It may therefore be applied to pancreatic lesions, or lymph nodes examination.
2.2. nCLE The principle of needle-based Confocal Laser Endomicroscopy (nCLE) is to image
organs within or adjacent to the GI or respiratory tracts with a miniprobe inserted
through an endoscopic needle. The fundamental technology as well as the principle of
operation of nCLE are substantially similar to pCLE.
3. Clinical evidence More than 100 patients have already underwent an nCLE procedure, in
the past studies. A first feasibility study enabled to define the final type of probe
which would fit into a EUSFNA needle, and the INSPECT study enabled to define
interpretation criteria on the micro-structure of pancreatic cysts. Less data is
available on pancreatic masses and lymph nodes, except for a few images done in the
first feasibility study.
4. Objectives
4.1. Cysts 4.1.1. The primary objective of the study is to assess the diagnostic
performance of the Cellvizio nCLE system in diagnosing pancreatic cysts, when associated
with other diagnostic information.
4.1.2. The secondary objectives are to assess the potential impact of the Cellvizio nCLE
system on patient management and validate the interpretation classification criteria
that were created during the previous INSPECT study on cysts.
4.2. Pancreatic masses and Lymph nodes 4.2.1. The primary objective of the study is to
define criteria of nCLE sequences in lymph nodes and pancreatic masses.
4.2.2. The secondary objectives are to evaluate feasibility and safety of the Cellvizio
nCLE during EUS-FNA procedures, build an atlas of images of nCLE sequences of pancreatic
masses and lymph nodes, and, finally, retrospectively assess the diagnostic performance
of nCLE in the diagnosis of pancreatic masses and lymph nodes, when associated with
other diagnostic information
5. Design This study will be conducted in three centers in France.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|